ClinicalTrials.gg
RecruitingNCT06547736Updated Jan 5, 2026

Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer

A Phase 2 interventional study of SHR-A2102 or/and HRS-4642 and SHR-A1904 or/and HRS-4642 in Pancreatic Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies testing KRAS G12D Inhibitor HRS-4642 in Pancreatic Neoplasms — 13 open to participants now, 13 under way, 2 of them phase 3. KRAS G12D Inhibitor HRS-4642 · Pancreatic Neoplasms.

Planned enrollment
3rd of 13
160 · median 60
Started
2024
with 2 others
Phase 2
7 of 13
7 open now
Primary completion
2027-03
later than 2 of 12 live
Registered
2nd of 13
by date
Lead sponsor
2 of 13
Fudan University

Among the 13 studies testing KRAS G12D Inhibitor HRS-4642 in Pancreatic Neoplasms, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2024, is one of 7 in phase 2, reaches primary completion later than 2 of the 12 other live ones, and was the 2nd registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

13 of the 13 studies testing KRAS G12D Inhibitor HRS-4642 in Pancreatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

About KRAS G12D Inhibitor HRS-4642

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing KRAS G12D Inhibitor HRS-4642 in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety, tolerability and efficacy of ADC drugs monotherapy or combination therapy with HRS-4642 or immunotherapy in subjects with locally advanced or metastatic pancreatic cancer.

Read the detailed description

This study is an open, single center, exploratory clinical trial aimed at evaluating the efficacy and safety of ADC drugs monotherapy or combination therapy with HRS-4642 or immunotherapy in the treatment of patients with unresectable locally advanced or metastatic pancreatic cancer.

This study experiment is divided into two stages: dose exploration stage and efficacy exploration stage. During the dose exploration phase, RP2D was determined based on the safety, tolerability, and preliminary efficacy data of ADC drugs monotherapy or combination therapy with HRS-4642 or immunotherapy, and then entered the efficacy exploration phase.

03

Conditions studied

  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients volunteered to participate in this study and signed ;
  2. Age: ≥18 and ≤75 years old, male or female;
  3. Advanced ( or unresectable) pancreatic cancer; and subjects must have at least one as defined by v1.1;
  4. (ECOG) Performance Status of 0 or 1;
  5. ≥ 12 weeks;
  6. Adequate marrow and organ function;
  7. Female participants of childbearing age must undergo a pregnancy test within one week before the start of the study medication, and the result is negative. They are willing to use a medically recognized and efficient method during the study period and within three months after the last administration of the study medication; For male participants whose partners are women of childbearing age, they should agree to use effective methods of contraception during the study period and within 6 months after the last study administration;

Exclusion criteria

Exclusion Criteria:

  1. Known to be allergic to the drug or any of its components;
  2. Systemic antitumor therapy was received 4 weeks before the start of the study, and palliative radiotherapy was completed within 14 days before the first dose;
  3. Have other active within 5 years;
  4. Accompanied by untreated or active central nervous system (CNS) ;
  5. Failure to recover toxicity and/or complications from previous interventions to ≤ Level 1 or the levels specified by inclusion and exclusion criteria;
  6. With interstitial lung disease, non-infectious pneumonia, severe and uncontrolled internal medicine diseases, acute infections, recent history of major surgery (within 28 days or not yet recovered from side effects);
  7. With gastrointestinal obstruction or symptoms and signs of gastrointestinal obstruction within 6 months before the start of treatment, but if surgical treatment has been performed and the obstruction is completely relieved, screening can be conducted;
  8. Within 6 months prior to entering the study, patients with severe cardiovascular and cerebrovascular thromboembolism;
  9. With congenital or acquired immune deficiency, such as people infected with , active (defined as hepatitis B virus surface antigen [HBsAg] in screening period is positive and HBV-DNA detection value ≥ 10000 copies/ml [2000 IU/ml] or active (defined as hepatitis C virus antibody [HCV Ab] in screening period is positive and HCV RNA is positive);
  10. With active pulmonary tuberculosis infection within one year prior to enrollment, or those with a history of active pulmonary tuberculosis infection more than one year ago but without formal treatment;
  11. Participated in other clinical studies or whose first medication is less than 4 weeks after the end of the previous clinical study (last medication), or whose study drug has a half-life of 5, whichever is shorter;
  12. High risk of pancreatitis, serum amylase and/or lipase concentrations ≥ 3 times , will be evaluated by the researchers;
  13. Uncontrollable mental illnesses and other known factors that affect the completion of research procedures, such as alcohol, drug or substance abuse, criminal detention, etc;
  14. Having undergone major surgeries other than diagnosis or within 28 days prior to the first administration; Experiencing traumatic minor surgery (biopsy, endoscopic examination, and drainage surgery) within 7 days prior to the first administration;
  15. Other situations that researchers believe should not be included.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Arm A

    SHR-A2102 monotherapy or combination therapy with HRS-4642 for treatment of advanced or metastatic PDAC.

    Drug: SHR-A2102 or/and HRS-4642

  • Experimental
    Arm B

    SHR-A1904 monotherapy or combination therapy with HRS-4642 for treatment of advanced or metastatic PDAC.

    Drug: SHR-A1904 or/and HRS-4642

  • Experimental
    Arm C

    SHR-A1811 monotherapy or combination therapy with HRS-4642 for treatment of advanced or metastatic PDAC.

    Drug: SHR-A1811 or/and HRS-4642

  • Experimental
    Arm D

    SHR-A2102 combination with HRS-4642 and immunotherapy for treatment of advanced or metastatic PDAC.

    Drug: SHR-A2102, HRS4642 and Adebrelimab

Interventions

  • DrugSHR-A2102 or/and HRS-4642

    Drug: SHR-A2102 SHR-A2102 will be administrated per dose level in which the patients are assigned. Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.

  • DrugSHR-A1904 or/and HRS-4642

    Drug: SHR-A1904 SHR-A1904 will be administrated per dose level in which the patients are assigned. Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.

  • DrugSHR-A1811 or/and HRS-4642

    Drug: SHR-A1811 SHR-A1811 will be administrated per dose level in which the patients are assigned. Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.

  • DrugSHR-A2102, HRS4642 and Adebrelimab

    Drug pages: Notiretatug rezetecanStudies of Notiretatug rezetecanNotiretatug rezetecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · KRAS G12D Inhibitor HRS-4642Studies of KRAS G12D Inhibitor HRS-4642KRAS G12D Inhibitor HRS-4642 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AdebrelimabStudies of AdebrelimabAdebrelimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: SHR-A2102 SHR-A2102 will be administrated per dose level in which the patients are assigned. Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned. Drug: Adebrelimab Adebrelimab will be administrated per dose level in which the patients are assigned.

06

What researchers measure

Primary outcomes

  1. Recommended phase II dose (RP2D)

    RP2D will be determined on the basis of evaluation on safety and efficacy data in dose escalation stages.

    Time frame: Approximately 12 months

  2. Objective Response Rate (ORR)

    Evaluated by RECIST v1.1.

    Time frame: Up to approximately 12 months]

Secondary outcomes

  1. Disease Control Rate (DCR)

    Evaluated by RECIST v1.1.

    Time frame: Up to approximately 12 months

  2. Duration of Response (DOR)

    Evaluated by RECIST v1.1.

    Time frame: Up to approximately 12 months

  3. Progression Free Survival (PFS)

    Time from the date of enrollment to of disease progression, or death of any cause, or date of lost follow-up, whichever comes first, otherwise subject data were censored at time last known disease free.

    Time frame: Up to approximately 12 months

  4. Overall survival (OS)

    Time from the date of enrollment to data of death from any cause, or date of lost follow-up, whichever comes first, and otherwise censored at time last known alive.

    Time frame: Up to approximately 12 months

  5. Adverse events (AEs)

    AEs are assessed by NCI-CTCAE v5.0

    Time frame: From the first drug administration to within 90 days for the last ADC durgs dose

07

Study locations

1 of 1 sites recruiting
  • Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • XianJun Yu, M.D., Ph.D. · Contactyuxianjun@fudanpci.org · +86-21-6417-5590
    • Xianjun Yu, M.D., Ph.D. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Mar 2027, 29 months after the start.

Of 327 non-industry phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's planned 29 months is below that.

Counting every sponsor, half of 396 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2024
First posted
Aug 9, 2024
StartActual
Oct 14, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06547736
Lead sponsor
Fudan University
Responsible party
Xian-Jun Yu (Professor, Fudan University) — Principal investigator
First posted
Aug 9, 2024
Start date
Oct 14, 2024
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jan 5, 2026

Study contacts

Si Shi, PHD
Contact
shisi@fudanpci.org
+86-021-64179375

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Notiretatug rezetecan · KRAS G12D Inhibitor HRS-4642 · Adebrelimab

Start the discussion